Low Flow Anesthesia in Morbid Obesity

NCT ID: NCT03913858

Last Updated: 2020-07-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-10

Study Completion Date

2020-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study to planned to research the efficacy of low-flow anesthesia on patients undergoing sleeve gastrectomy due to morbid obesity on respiratory functions after surgery by examining FEV1 and FVC values and FEV1/FVC ratio.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Morbid obese patients undergoing sleeve gastrectomy due to morbid obesity after 01.01.2019 will be randomly divided into 2 groups with controls. To prevent selection bias in the study, numbers will be produced at random. The produced numbers will be determined as 0: control and 1: experiment groups and patients will be divided into groups as such. Random numbers will be generated by the MedCalc 18.2.1. program (MedCalc Statistical Software MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2018). Group 1 is determined as patients to be administered high-flow anesthesia, while Group 2 will be administered low-flow anesthesia. After anesthesia induction, Group 1 will have 4 liters/minute (50% O2 50%) flow administered, while patients in Group 2 will have 1 liter/minute (50% O2, 50% air) flow administered. The study included adult patients who signed the voluntary consent form aged from 18-65 years, American Society of Anesthesiologists (ASA) III, and body mass index (BMI) \>40. Inclusion criteria for the study are no alcohol or drug addiction or diagnosis of chronic obstructive pulmonary disease (COPD) during routine preoperative assessment by chest diseases, FEV1/FVC ratio, FEV1 and FVC values within normal limits and no previous abdominal surgery.

Those with stop-bang score below 4 will be included in the study. On the day of surgery, all patients had FEV1, FVC value and FEV1/FVC ratio examined by a single anesthesia technician using a manual RST device without the knowledge of the anesthesia expert.

Pressure tests and calibration of the anesthesia device is performed each morning for every surgery. After calibration the mechanical ventilator alarm limits for ins O2 are lower limit 40%, EtCO2 35-45 mmHg, min Vol (tidal volume in 1 min x frequency) according to the patient ± 0.5. After patient is placed on the operating table in ramp position, all patients are monitored with triple route ECG, pulse oximetry and pressure cuff. The clinical protocol for all patients undergoing sleeve gastrectomy includes BIS (bispectral index) and TOF (train of four) monitoring. Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. Patients were ventilated with 6 L/min 60% O2 for 2 minutes. Patients were endotracheally intubated with a Macintosh laryngoscope. In addition to assessment of respiratory sounds linked to obesity with auscultation, EtCO2 capnography was used to confirm the efficacy of intubation. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Sevoflurane percentage was changed to ensure MAC (minimum alveolar concentration of 0.6-1.1 for BIS score of 40-60 for maintenance. During ventilation in PRVC mode, Group 1 had 4 liter/minute (50% O2, 50% air) flow administered, while Group 2 had 3 L/min 4% for Sevoflurane the first 3 minutes as wash-in. Then flow was administered at 1 L/min (50% O2, 50% air). According to ideal weight, mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. In Group 1, sevoflurane percentage was set to correlate with BIS monitoring. In Group 2, after intubation the sevoflurane percentage was set to a higher percentage to reach the desired MAC value. Every 5 minutes during surgery, MAC, BIS, mean arterial pressure, peak heart rate, sPO2, etCO2, inSO2, frequency and PEEP values were recorded. In Group 2, 5 minutes before the end of surgery, flow was increased from 1 L to 4 L for wash-out. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered. Five minutes before the end of the operation patient-controlled SIMV+VE mode with trigger setting of 6 was organized. At the end of surgery, patients were administered 2 mg/kg sugammadex according to ideal weight. When the patients trigger setting reaches muscle power it was lowered to zero. When trigger is zero and there is sufficient tidal volume to reach TOF (train of four) value \>90% and BIS score is 80-100, patients were extubated. They were sent to the recovery room. In recovery the ARISCAT risk index was calculated. Later when modified Aldrete scoring system is ≥9, patients were sent to the ward.

After surgery, mobilization and respiratory physiotherapy were provided in the 2nd hour. Vital signs including mean arterial pressure (MAP) were recorded in the postoperative period with 20 mg tenoxicam I.V. administered in the 1st hour. The PCA device was set with tramadol 300 mg/100 ml, bolus 10 mg, lock time 12 minutes without basal infusion. Patients with numeric rating scale (NRS) scores ≥4 had a rescue dose of 4 mg morphine I.V. administered. Each patient began oral intake (water) in the postoperative 24th hour, with early mobilization. A second dose of tenoxicam I.V. was administered in the postoperative 8th hour.

In the 24th hour postoperative, patients had analgesia to ensure VAS score is below 4, with RFT repeated by the same doctor who performed RFT preoperatively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Morbid Obesity Anesthesia Complication Anesthesia; Functional

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

high-flow anesthesia

Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 1 had 4 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.

Group Type OTHER

Obesity Surgery with High-Flow Anesthesia

Intervention Type PROCEDURE

Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.

low-flow anesthesia

Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 2 had 1 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.

Group Type OTHER

Obesity Surgery with Low-Flow Anesthesia

Intervention Type PROCEDURE

Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Obesity Surgery with Low-Flow Anesthesia

Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.

Intervention Type PROCEDURE

Obesity Surgery with High-Flow Anesthesia

Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Procedure/Anesthesia Procedure/Anesthesia

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* american Society of Anesthesiologists (ASA) III
* body mass index (BMI) \>40.
* FEV1/FVC ratio within normal limits
* FEV1 and FVC values within normal limits
* those with stop-bang score below 4

Exclusion Criteria

* alcohol abuse
* drug abuse
* previous abdominal surgery.
* chronic obstructive pulmonary disease (COPD)
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bakirkoy Dr. Sadi Konuk Research and Training Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Evrim Kucur Tulubas

Department of Anesthesiology and Critical Care Medicine Attending Anaesthesia

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Evrim Kucur Tulubas, Dr

Role: PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bakırköy Dr. Sadi Konuk Trainig And Research Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Evrim Kucur Tulubas

Identifier Type: OTHER

Identifier Source: secondary_id

Obesity Surgery FEV1/FVC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Preoperative Evaluation of Airway
NCT03597880 COMPLETED NA